Carteolol is a non-selective beta-adrenergic blocker with intrinsic sympathomimetic activity, primarily used to reduce intraocular pressure in glaucoma and ocular hypertension by decreasing aqueous humor production in the eye. It was developed in the 1970s during the rapid advancement of beta-blocker research following earlier drugs like propranolol, and was later introduced as an ophthalmic preparation after proving effective and well tolerated. Over the years, carteolol has become an established option in glaucoma management due to its sustained action and favorable safety profile.
Image
